Ismail Selvi1, Umut Demirci2, Nazan Bozdogan3, Halil Basar4. 1. Department of Urology, Karabük University Training and Research Hospital, 78200, Karabük, Turkey. ismselvi33@hotmail.com. 2. Department of Medical Oncology, Health Science University Dr, Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey. 3. Department of Pathology, Health Science University Dr, Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey. 4. Department of Urology, Health Science University Dr, Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey.
Abstract
PURPOSE: This study aimed to evaluate the density of CD8+ and CD3+ tumor-infiltrating lymphocytes (TILs) and determine whether the immunoscore has any prognostic effect on the oncological outcomes in patients with clear cell renal cell carcinoma (RCC). MATERIALS AND METHODS: A total of 129 patients diagnosed with clear cell RCC following radical or partial nephrectomy between 2009 and 2014 were retrospectively analyzed. Both tumor core (CT) and the invasive margin of nephrectomy specimens were assessed. The specimens were immunostained for anti-CD8+ and anti-CD3+ TILs. The patients were divided into three groups (favorable, intermediate, and poor risk) according to immunoscore levels. RESULTS: In the multivariate analysis, a favorable immunoscore (I3-4) was associated with prolonged disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) (HR 2.652, 2.848, and 2.933, respectively; all p < 0.001). The lower Fuhrman grade and pathological tumor-node-metastasis (TNM) stage had better DFS, PFS, and OS, whereas prolonged PFS was associated with a higher density of CD8+ CT (HR 1.602, 95% CI 0.934-3.470; p = 0.014). The shorter DFS, PFS, and OS were observed in the group with poor immunoscore (I0-1) at the early TNM stage of RCC (p < 0.001). In the metastatic subgroup analysis, the immunoscore showed better estimation than the International Metastatic RCC Database Consortium model and the Memorial Sloan-Kettering Cancer Center risk model for progression and OS (p < 0.001). CONCLUSION: The additional contributions of immunoscore to TNM stage, Fuhrman grade, and the WHO/ISUP 2016 grade for estimating oncological outcomes were found in ROC analysis. According to our preliminary results, immunoscore can be a promising prediction tool in clear cell RCC for postoperative oncological outcomes following nephrectomy.
PURPOSE: This study aimed to evaluate the density of CD8+ and CD3+ tumor-infiltrating lymphocytes (TILs) and determine whether the immunoscore has any prognostic effect on the oncological outcomes in patients with clear cell renal cell carcinoma (RCC). MATERIALS AND METHODS: A total of 129 patients diagnosed with clear cell RCC following radical or partial nephrectomy between 2009 and 2014 were retrospectively analyzed. Both tumor core (CT) and the invasive margin of nephrectomy specimens were assessed. The specimens were immunostained for anti-CD8+ and anti-CD3+ TILs. The patients were divided into three groups (favorable, intermediate, and poor risk) according to immunoscore levels. RESULTS: In the multivariate analysis, a favorable immunoscore (I3-4) was associated with prolonged disease-free survival (DFS), progression-free survival (PFS), and overall survival (OS) (HR 2.652, 2.848, and 2.933, respectively; all p < 0.001). The lower Fuhrman grade and pathological tumor-node-metastasis (TNM) stage had better DFS, PFS, and OS, whereas prolonged PFS was associated with a higher density of CD8+ CT (HR 1.602, 95% CI 0.934-3.470; p = 0.014). The shorter DFS, PFS, and OS were observed in the group with poor immunoscore (I0-1) at the early TNM stage of RCC (p < 0.001). In the metastatic subgroup analysis, the immunoscore showed better estimation than the International Metastatic RCC Database Consortium model and the Memorial Sloan-Kettering Cancer Center risk model for progression and OS (p < 0.001). CONCLUSION: The additional contributions of immunoscore to TNM stage, Fuhrman grade, and the WHO/ISUP 2016 grade for estimating oncological outcomes were found in ROC analysis. According to our preliminary results, immunoscore can be a promising prediction tool in clear cell RCC for postoperative oncological outcomes following nephrectomy.
Authors: Padmanee Sharma; Yu Shen; Sijin Wen; Sachiko Yamada; Achim A Jungbluth; Sacha Gnjatic; Dean F Bajorin; Victor E Reuter; Harry Herr; Lloyd J Old; Eiichi Sato Journal: Proc Natl Acad Sci U S A Date: 2007-02-27 Impact factor: 11.205
Authors: Bernhard Mlecnik; Gabriela Bindea; Helen K Angell; Pauline Maby; Mihaela Angelova; David Tougeron; Sarah E Church; Lucie Lafontaine; Maria Fischer; Tessa Fredriksen; Maristella Sasso; Amélie M Bilocq; Amos Kirilovsky; Anna C Obenauf; Mohamad Hamieh; Anne Berger; Patrick Bruneval; Jean-Jacques Tuech; Jean-Christophe Sabourin; Florence Le Pessot; Jacques Mauillon; Arash Rafii; Pierre Laurent-Puig; Michael R Speicher; Zlatko Trajanoski; Pierre Michel; Richard Sesboüe; Thierry Frebourg; Franck Pagès; Viia Valge-Archer; Jean-Baptiste Latouche; Jérôme Galon Journal: Immunity Date: 2016-03-15 Impact factor: 31.745
Authors: Jérôme Galon; Franck Pagès; Francesco M Marincola; Helen K Angell; Magdalena Thurin; Alessandro Lugli; Inti Zlobec; Anne Berger; Carlo Bifulco; Gerardo Botti; Fabiana Tatangelo; Cedrik M Britten; Sebastian Kreiter; Lotfi Chouchane; Paolo Delrio; Hartmann Arndt; Martin Asslaber; Michele Maio; Giuseppe V Masucci; Martin Mihm; Fernando Vidal-Vanaclocha; James P Allison; Sacha Gnjatic; Leif Hakansson; Christoph Huber; Harpreet Singh-Jasuja; Christian Ottensmeier; Heinz Zwierzina; Luigi Laghi; Fabio Grizzi; Pamela S Ohashi; Patricia A Shaw; Blaise A Clarke; Bradly G Wouters; Yutaka Kawakami; Shoichi Hazama; Kiyotaka Okuno; Ena Wang; Jill O'Donnell-Tormey; Christine Lagorce; Graham Pawelec; Michael I Nishimura; Robert Hawkins; Réjean Lapointe; Andreas Lundqvist; Samir N Khleif; Shuji Ogino; Peter Gibbs; Paul Waring; Noriyuki Sato; Toshihiko Torigoe; Kyogo Itoh; Prabhu S Patel; Shilin N Shukla; Richard Palmqvist; Iris D Nagtegaal; Yili Wang; Corrado D'Arrigo; Scott Kopetz; Frank A Sinicrope; Giorgio Trinchieri; Thomas F Gajewski; Paolo A Ascierto; Bernard A Fox Journal: J Transl Med Date: 2012-10-03 Impact factor: 5.531
Authors: Jérôme Galon; Franck Pagès; Francesco M Marincola; Magdalena Thurin; Giorgio Trinchieri; Bernard A Fox; Thomas F Gajewski; Paolo A Ascierto Journal: J Transl Med Date: 2012-01-03 Impact factor: 5.531
Authors: Jérôme Galon; Bernhard Mlecnik; Gabriela Bindea; Helen K Angell; Anne Berger; Christine Lagorce; Alessandro Lugli; Inti Zlobec; Arndt Hartmann; Carlo Bifulco; Iris D Nagtegaal; Richard Palmqvist; Giuseppe V Masucci; Gerardo Botti; Fabiana Tatangelo; Paolo Delrio; Michele Maio; Luigi Laghi; Fabio Grizzi; Martin Asslaber; Corrado D'Arrigo; Fernando Vidal-Vanaclocha; Eva Zavadova; Lotfi Chouchane; Pamela S Ohashi; Sara Hafezi-Bakhtiari; Bradly G Wouters; Michael Roehrl; Linh Nguyen; Yutaka Kawakami; Shoichi Hazama; Kiyotaka Okuno; Shuji Ogino; Peter Gibbs; Paul Waring; Noriyuki Sato; Toshihiko Torigoe; Kyogo Itoh; Prabhu S Patel; Shilin N Shukla; Yili Wang; Scott Kopetz; Frank A Sinicrope; Viorel Scripcariu; Paolo A Ascierto; Francesco M Marincola; Bernard A Fox; Franck Pagès Journal: J Pathol Date: 2014-01 Impact factor: 7.996